Table 6.

Specific inhibitors against RNA modification regulators

Target	Drug	Cancer	Effect	Ref.
FTO	Rhein	AML	Anti-leukemia efficacy in vitro and in vivo	409
	MA2	GBM	Suppresses cell proliferation and tumor progression	410
	R-2HG	AML/GBM	Antitumor effect, synergizing with first-line chemotherapy agents	412
	FB23-2	AML	Anti-leukemia efficacy in vitro and in vivo	413
	CS1/2	AML	Potent anti-leukemia efficacy in mouse models, sensitize leukemia cells to T-cell cytotoxicity, overcomes immune evasion	402
	Dac15	Melanoma	Promotes activation and effector state of T cell, improving anti-PD1 blockade	248
	18097	BRCA	Restrain in vivo growth and lung colonization	414
	FTO-43	GC/AML/GBM	Potent anti-tumor effects in mouse model	415
	C6	ESCC	Anti-tumor efficacy in vitro and in vivo	416
ALKBH5	ALK-04	Melanoma	Improve anti-PD-1 therapy efficiency	404
	Compound 1/2	AML	Anti-proliferative effects in specific AML cell lines	417
METTL3	UZH1a	AML	Suppress proliferation and viability of tumor cells	418
	UZH2	AML/PC	More potent anti-proliferative effects in vitro	419
	STM2457	AML	Anti-leukemia efficacy in vitro and in vivo	420
TRMT6/TRMT61A	Thiram	HCC	Suppresses HCC growth in preclinical models	421